Interventional Glaucoma

The Elios procedure increased aqueous humor outflow in all investigated eyes, but further studies are needed to correlate these improvements with its clinical efficacy.

A systematic review and meta-analysis highlights the safety and efficacy of excimer laser trabeculostomy as an implant-free MIGS procedure for managing open-angle glaucoma and ocular hypertension, either alone or in combination with cataract surgery.

The funding will help further the glaucoma program alongside new board member Carol Gallagher.

The state-of-the-art facility more than doubles the institute’s footprint, enhancing patient care, research, and education.

Direct selective laser trabeculoplasty enhances the experience for both patients and physicians, he notes, while also mitigating issues related to poor adherence and ocular surface disease from topical therapy.

Ying Han, MD, PhD discusses glaucoma management strategies, including transitioning care between ophthalmologists and optometrists, improving diagnosis, and the hope for future glaucoma developments.

SightScore is a saliva test that looks at millions of genetic variants in the patient’s genome to create a personalized polygenic risk score for glaucoma.

The new first-line laser treatment for glaucoma and ocular hypertension will be unveiled at the 2025 American Glaucoma Society annual meeting in Washington, DC, from February 26 to March 2.

At the Envision Summit 2025 in San Juan, Puerto Rico, Rachel Simpson, MD, talked about new developments in glaucoma treatment and really how to tailor glaucoma treatment to the patient.

The focus in recent years has shifted to reducing the long-term burden of medical therapy, minimizing the risk of medication toxicity and persistent ocular surface disease.

At the Envision Summit 2025 in San Juan, Puerto Rico, Jessica Steen, OD, FAAO talked with glaucoma surgeons on the importance of comanaging patients throughout their lifetime.

Yvonne Ou, MD, a professor of ophthalmology at the University of California San Francisco, spoke about lifestyle modifications for glaucoma at this year's Glaucoma 360 meeting.

The 2 phase II trials, Osprey and Apteryx successfully met all primary and secondary endpoints.

M. Roy Wilson, presented the Shaffer-Hetherington-Hoskins Lecture at the Glaucoma 360 meeting held in San Francisco, California. This lecture was entitled, "Rethinking Race as a Risk Factor for Glaucoma: What Really Matters?"

Ophthalmology Times spoke with Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis about how her research can align with human glaucoma research to move the entire field

Sunita Radhakrishnan, MD, shares insights on the use of electric neurostimulation and its potential use in the treatment of glaucoma, as evidenced by its current use in Europe and the upcoming trials for use in the US.

Shan Lin, MD, speaks to the new MIGS entering the glaucoma space and providing additional options for patients and providers as they work to preserve vision and work towards a better future for glaucoma treatment options.

Andrew Iwach, MD, co-founder of the Glaucoma 360 meeting shares that value this meeting has for residents and fellows as they embark on their careers and the future additions to the meeting that will include retina discussions.

Inder Paul Singh, MD, speaks to the potential of artificial intelligence (AI) in the management of the glaucoma disease state as well as the current challenges of drug delivery in treating patients with glaucoma.

John Berdahl, MD, discusses a non-surgical, non-drug treatment for glaucoma approved by the FDA in 2024. The pump uses negative pressure to lower eye pressure by an average of 39% in clinical trials, with a good safety profile.

Patients’ near visual needs is important when prescribing medications for glaucoma treatment

Real-world scenarios showcase a shift in treatment paradigms

Through its ophthalmic program, Mercy Ships provides critical eye surgeries and trains local professionals, ensuring sustainable eye care for the future.

Recipients will be awarded $100,000 to support a collaborative project related to glaucoma

The iDose platform is designed to address ubiquitous patient non-adherence and chronic side effects associated with topical medications by providing 24/7 release of medication.

Himani Goyal, MD, discusses a complex glaucoma case involving persistent intraocular pressure elevation despite multiple treatment procedures, focusing on advanced management strategies and decision-making for challenging cases.

Himani Goyal, MD, explores a case of glaucoma treated with an intracameral implant, evaluating its efficacy in managing intraocular pressure and its role in optimizing long-term glaucoma care.

Himani Goyal, MD, discusses a case of cataracts and minimally invasive glaucoma surgery (MIGS) combination, highlighting the benefits of this approach in managing both cataracts and glaucoma in a single procedure for improved patient outcomes.

The long-term analysis show clinically and statistically significant reductions in intraocular pressure through up to 36 months postoperatively.